Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression (2011)
- Authors:
- USP affiliated authors: DOREA, EGIDIO LIMA - HU ; HIRATA, MARIO HIROYUKI - FCF ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidades: HU; FCF
- Subjects: EXPRESSÃO GÊNICA; POLIMORFISMO
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Journal of Atherosclerosis and Thrombosis
- ISSN: 1340-3478
- Volume/Número/Paginação/Ano: v. 18, n. 8, p. 640-651, 2011
-
ABNT
CERDA, Alvaro et al. Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression. Journal of Atherosclerosis and Thrombosis, v. 18, n. 8, p. 640-651, 2011Tradução . . Acesso em: 16 abr. 2024. -
APA
Cerda, A., Genvigir, F. D. V., Rodrigues, A. C., Willrich, M. A. V., Dórea, E. L., Bernik, M. M. S., et al. (2011). Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression. Journal of Atherosclerosis and Thrombosis, 18( 8), 640-651. -
NLM
Cerda A, Genvigir FDV, Rodrigues AC, Willrich MAV, Dórea EL, Bernik MMS, Arazi SS, Oliveira R de, Hirata MH, Hirata RDC. Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression. Journal of Atherosclerosis and Thrombosis. 2011 ; 18( 8): 640-651.[citado 2024 abr. 16 ] -
Vancouver
Cerda A, Genvigir FDV, Rodrigues AC, Willrich MAV, Dórea EL, Bernik MMS, Arazi SS, Oliveira R de, Hirata MH, Hirata RDC. Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression. Journal of Atherosclerosis and Thrombosis. 2011 ; 18( 8): 640-651.[citado 2024 abr. 16 ] - Relationships among CYP3A4 and CYP3A5 haplotypes, mRNA expression, CYP3A activity and atorvastatin response in hypercholesterolemic individuals
- Differentiation of african components of ancestry to stratify groups in a case-control study of a brazilian urban population
- Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response
- Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin
- The contribution of genetic polymorphisms in 60 candidate genes to variability in atorvastatin response
- CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia
- Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
- Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
- Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin
- Expression of inflammatory response genes in pbmc from type 2 diabetes individuals treated with simvastatin and ezetimibe
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
